Spravato Insurance Coverage in Tennessee in 2026

Spravato (esketamine nasal spray) has been FDA-approved for treatment-resistant depression since 2019, and in 2026, insurance coverage in Tennessee has become more established — though far from automatic. TennCare and major commercial payers like BlueCross BlueShield of Tennessee cover Spravato under certain conditions, but prior authorization, step therapy documentation, and REMS compliance are all required pieces of the process.

This post explains how Spravato coverage works in Tennessee, what the major payers require, and what steps Tennessee patients can take to pursue coverage.

This is educational information about insurance processes, not medical or legal advice.

Why Spravato Has Better Coverage Than IV Ketamine

Spravato is esketamine — a chemical relative of ketamine — delivered as a nasal spray. The FDA approved it specifically for treatment-resistant depression (ICD-10 F32.9, F33.2) in adults who have not adequately responded to at least two antidepressant trials, and for major depressive disorder with acute suicidal ideation. You can review the FDA’s approval information at FDA.gov.

That specific FDA indication is the reason Spravato has insurance coverage pathways that off-label IV ketamine does not. Tennessee payers require an FDA-approved indication as a prerequisite for coverage. Because off-label IV ketamine lacks an FDA psychiatric indication, it remains largely out-of-pocket for most insured patients in Tennessee.

Spravato sessions are conducted in a certified healthcare setting. After the patient self-administers the nasal spray, a mandatory two-hour on-site monitoring period is required after each dose.

TennCare Coverage for Spravato

TennCare, Tennessee’s Medicaid program, covers Spravato for qualifying members through its managed care organizations. The largest TennCare MCOs are BlueCare Tennessee (operated by BCBS of Tennessee) and UnitedHealthcare Community Plan of Tennessee. Coverage policies can vary by MCO, so the specific requirements you face depend on which plan you are enrolled in.

In general, TennCare Spravato coverage requires:

• A documented treatment-resistant depression diagnosis (ICD-10 F32.9 or F33.2)
• Evidence that at least two adequate antidepressant trials have failed (appropriate dose and duration)
• A prior authorization submitted by the treating clinician and approved before treatment begins

“Adequate trial” documentation is important. Your clinician’s records should reflect that prior antidepressants were prescribed at therapeutic doses for a sufficient duration — not simply that they were tried briefly or at a low dose.

If a TennCare prior authorization is denied, the appeals process is a meaningful option. Your clinician can submit additional clinical documentation supporting medical necessity. Tennessee’s managed care appeal process includes both internal and external review options.

Contact your specific TennCare MCO for the exact prior authorization form and criteria — these vary between BlueCare, UnitedHealthcare, and other participating MCOs.

BlueCross BlueShield of Tennessee

BCBS of Tennessee is the dominant commercial insurer in Tennessee and also administers BlueCare Tennessee (the TennCare MCO). On commercial plans — employer-sponsored and individual market — BCBS of Tennessee covers Spravato on many plans as of 2026, subject to:

• Prior authorization
• Documentation of a treatment-resistant depression diagnosis (F32.9, F33.2)
• Evidence of step therapy — prior antidepressant failures at appropriate doses and duration
• Treatment at a REMS-certified site

BCBS of Tennessee processes prior authorizations through its specialty pharmacy or medical management division. The prescribing clinic initiates and submits the request. Patients should ask the clinic what documentation they plan to submit and whether they have prior experience with BCBS of Tennessee prior authorizations.

Denials can be appealed, and clinicians can request a peer-to-peer review with the plan’s medical director as part of the appeal.

Cigna and Aetna in Tennessee

Cigna and Aetna plans are present in Tennessee’s commercial market, particularly through employer-sponsored coverage. Both cover Spravato on many plans with similar prior authorization and step therapy requirements. If you have Cigna or Aetna coverage in Tennessee, the approach is the same: your prescribing clinician submits the prior authorization, documents the diagnosis and prior treatment failures, and confirms REMS certification of the dispensing site.

Practical Steps for Tennessee Patients

If you are in Tennessee and pursuing Spravato coverage, here is a practical sequence:

1. Confirm your diagnosis is documented. Your clinician must document treatment-resistant depression (F32.9 or F33.2) with evidence of prior treatment failures.
2. Ask your prescribing clinician to initiate the prior authorization. This is a clinical process — the clinic submits the request to your insurer or TennCare MCO.
3. Confirm the clinic is REMS-certified. Every Spravato dispensing site must be FDA REMS-certified. This is both a legal requirement and a payer requirement.
4. Get a written cost estimate. Ask the clinic to break out drug costs from the monitoring visit fee and what your out-of-pocket exposure will be under your specific plan.
5. Ask about the Janssen patient assistance program. The manufacturer offers programs that may reduce out-of-pocket costs for eligible commercially insured or uninsured patients.
6. Ask about both induction and maintenance phases. Prior authorization requirements can differ between the induction phase (twice weekly for four weeks) and maintenance. Confirm your plan covers both.

Contact us for help finding Tennessee Spravato providers experienced with TennCare and BCBS of Tennessee prior authorizations.

IV Ketamine in Tennessee: A Note on Coverage

Off-label IV ketamine infusions are not covered by TennCare or most Tennessee commercial plans as of 2026. Evaluation and management visits (CPT 99213/99214) and psychiatric intake visits (CPT 90791) associated with a ketamine treatment program may be billable to insurance, but the infusion itself is generally an out-of-pocket expense.

For Tennessee patients facing cost barriers, SAMHSA’s findtreatment.gov tool at findtreatment.gov can help identify publicly funded behavioral health resources across the state.

---

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.